Prescriptions Of Anti-Obesity GLP-1 Medications For Adolescents Increased Between 2023 & 2024 

Prescriptions of one of the two anti-obesity GLP-1 medications approved for use by adolescents ages 12 to 17 in the United States have increased, according to a recent study of commercial claims data. The study found that the number of prescriptions increased from 9.9 per 100,000 in 2023 to 14.8 per 100,000 in 2024. During 2024, first-time prescriptions of semaglutide as an anti-obesity medication (brand name Wegovy) were 17.7 times higher than first-time prescriptions for liraglutide (brand name Saxenda).  

The study included 1.27 million adolescents without type 2 diabetes . . .